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Abstract
Background and purpose: To determine in vivo magnetic re -
sonance spectroscopy (MRS) characteristics of intracranial
glial tumours and to assess MRS reliability in glioma grad-
ing and discrimination between different histopathological
types of tumours.
Material and methods: Analysis of spectra of 26 patients with
glioblastomas, 6 with fibrillary astrocytomas, 4 with anaplas-
tic astrocytomas, 2 with pilocytic astrocytoma, 3 with oligo-
dendrogliomas, 3 with anaplastic oligodendrogliomas and 
17 control spectra taken from healthy hemispheres.
Results: All tumours’ metabolite ratios, except for Cho/Cr in
fibrillary astrocytomas (p = 0.06), were statistically signi -
ficantly different from the control. The tumours show ed
decreased Naa and Cr contents and a high Cho signal. 
The Lac-Lip signal was high in grade III astrocytomas and
glioblastomas. Reports that Cho/Cr ratio increases with
glioma’s grade whereas Naa/Cr decreases were not confirmed.
Anaplastic astrocytomas compared to grade II astrocytomas
had a statistically significantly greater mI/Cr ratio (p = 0.02).
In pilocytic astrocytomas the Naa/Cr value (2.58 ± 0.39) was
greater, whilst the Cho/Naa ratio was lower (2.14 ± 0.64)
than in the other astrocytomas. The specific feature of oligo-
dendrogliomas was the presence of glutamate/glutamine peak
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Streszczenie
Wstêp i cel pracy: Ustalenie charakterystyki spektroskopii
magnetycznego rezonansu j¹drowego (magnetic resonance spec-
troscopy – MRS) u chorych z nowotworami wewn¹trzczaszko-
wymi pochodzenia glejowego oraz ocena przydatnoœci tego bada-
nia w diagnostyce ró¿nicowej typów histologicznych glejaków.
Materia³ i metody: Przeprowadzono analizê widm MRS
nowotworów u 26 chorych z glejakami wielopostaciowymi, 
6 z gwiaŸ dziakami w³ókienkowymi, 4 z gwiaŸdziakami ana-
plastycznymi, 2 z w³osowatokomórkowymi, 3 ze sk¹podrze-
wia kami, 3 ze sk¹podrzewiakami anaplastycznymi oraz 
17 widm kontrolnych pochodz¹cych ze zdrowych pó³kul mózgu.
Wyniki: Wszystkie wskaŸniki metaboliczne w przypadkach
nowotworów, z wyj¹tkiem Cho/Cr w gwiaŸdziakach w³ókien-
kowych (p = 0,06), ró¿ni³y siê znamiennie od tych w grupie
kontrolnej. Nowotwory wykazywa³y zmniejszon¹ zawartoœæ Naa
i Cr oraz wysoki sygna³ Cho. Sygna³ Lac-Lip by³ wysoki
w gwiaŸdziakach III stopnia wg WHO i glejakach wielopo-
staciowych. Nie uda³o siê potwierdziæ doniesieñ, ¿e wskaŸnik
Cho/Cr roœnie, a wskaŸnik Naa/Cr maleje wraz ze wzrostem
stopnia z³oœliwoœci glejaka. GwiaŸdziaki anaplastyczne wyka-
zywa³y znamiennie wy¿szy wskaŸnik mI/Cr (p = 0,02) w po -
równaniu z gwiaŸdziakami II stopnia wg WHO. W gwiaŸdzia -
kach w³osowatokomórkowych wartoœæ Naa/Cr (2,58 ± 0,39)
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Introduction
The progress of magnetic resonance imaging (MRI)
has considerably facilitated diagnosis of brain tumours.
One of its particular applications is magnetic resonance
spectroscopy in vivo (MRS). To date, a number of re -
ports have presented a correlation between MRS spec-
tra and neuropathology of brain tumours [1-7]. This
method proved to be helpful in in vivo grading of gliomas
[8-11], discrimination between lymphomas and gliomas
[12,13], metastases and gliomas [14], as well as neo-
plasms and non-neoplastic lesions [15,16]. It ap pears
that MRS may add to the diagnostic accuracy of MRI
[17], having also certain prognostic value in pa tients with
malignant gliomas [18,19].
The aim of this study was to determine in vivo MRS
characteristics in patients operated on at the Department
of Neurosurgery, Medical University of Lodz, Poland
and to compare these data with reports available in 
the literature, as well as to assess MRS reliability in
glioma grading and discrimination between different
histopathological types of tumours.
Material and methods
The study involved 89 patients with brain tumours
who underwent neurosurgery at the Department of Neu-
 rosurgery of the Medical University in Lodz. There
were 38 men and 51 females aged from 19 to 75. The
study evaluated only patients with medium and large
tumours i.e. the cases in which the investigator was able
to set a voxel volume from 1 to 8 cubic centimetres. All
patients gave informed consent to the study. The study
protocol has been accepted by the University Bioethical
Committee for Experiments on Human Subjects. 
The MR examinations were carried out as part of the
eTumour project (LSHC-CT-2004-503094) – Web
Accessible MR Decision Support System For Brain
Tumour Diagnosis And Prognosis, Incorporating In
Vivo And Ex Vivo Genomic And Metabolimic Data
(http://cordis.europa.eu/fetch?).
The patients had an MRS examination a day prior
to tumour surgery. This was performed with a Siemens
Magnetom Vision scanner with magnetic flux density
of 1.5T. First, T1-weighted images of a tumour were ob -
tained in three planes (coronal, sagittal and axial) after
intravenous administration of the contrast medium –
gadolinium. Subsequently, the voxel was set in a solid
and most strongly contrast-enhancing part of the tumour
as seen in Fig. 1. The MRS examination was done by
means of single voxel spectroscopy (SVS), employing
Glx. However, this peak was absent in two out of three
anaplastic oligodendrogliomas. Characteristically, the latter
tumours had a high Lac-Lip signal. 
Conclusions: MRS in vivo cannot be used as a reliable
method for glioma grading. The method is useful in dis-
crimination between WHO grade I and WHO grade II
astrocytomas as well as oligodendrogliomas from other
gliomas.
Key words: magnetic resonance spectroscopy, glioblastoma,
astrocytoma, oligodendroglioma.
by³a wiêksza, a Cho/Naa mniejsza (2,14 ± 0,64) ni¿ w innych
gwiaŸdziakach. Sk¹podrzewiaki charakteryzowa³a obecnoœæ
szczytu glutaminianu/glutaminy (Glx), którego jednak nie
obserwowano w 2 spoœród 3 przypadków sk¹podrzewiaków
anaplastycznych. Dla tych ostatnich symptomatyczna by³a
obecnoœæ silnego sygna³u Lac-Lip.
Wnioski: Badanie MRS in vivo nie jest niezawodn¹ metod¹
ró¿nicuj¹c¹ glejaki wewn¹trzczaszkowe. Wydaje siê u¿yteczne
w diagnostyce ró¿nicowej gwiaŸdziaków I i II stopnia wg
WHO oraz w odró¿nianiu sk¹podrzewiaków od pozosta³ych
glejaków.
S³owa kluczowe: MRS, glejak wielopostaciowy, gwiaŸdziak,
sk¹podrzewiak.
Fig. 1. The voxel placed in the solid and enhancing part of anaplastic oligo-
dendroglioma shown in three planes (transverse, sagittal and coronal) and
the characteristic spectrum of this neoplasm
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both short echo time (STEAM sequence with TE =
= 30 ms or PRESS sequence with TE = 30 ms) and
long echo time (PRESS TE = 136 ms or PRESS 
TE = 135 ms). In both instances the repetition time
(TR) was 2000 ms. On average, 256 signal acquisitions
were done in each sequence.
The control spectra of normal brain were obtained
from the voxel placed in a healthy cerebral hemisphere
in 17 patients.
All spectra were processed by means of the computer
program Magnetic Resonance User Interface (MRUI,
v.3) according to the protocol of the eTumour project
[20]. The processing included synchronization of the
spectrum phase with the reference spectrum represent-
ing only the signal of water, apodisation and removal of
the signal of water employing the method of Hankel
Lanczos singular values decomposition (HLSVD).
Qualitative analysis of the spectra included recogni-
tion of signals from the following metabolites: N-acetyl
aspartate (Naa, chemical shift equals 2.02 ppm), choline
(Cho – 3.22 ppm), creatinine (Cr – 3.02 ppm), alanine
(Ala – 1.48 ppm), myo-inositol (mI – 3.56 ppm), glu-
tamate (Glx – 2.35 ppm), lipids (Lip – 0.9 ppm and 
1.3 ppm), and lactates (Lac – 1.33 ppm). The Advanced
Method for Accurate, Robust and Efficient Spectral Fit-
ting (AMARES) [21] was used for quantitative analy-
sis. Its results were given as relative values, i.e. fractions
of the signal amplitudes: Cho/Cr, Naa/Cr, Cho/Naa,
mI/Cr. Contents of lactates and lipids were looked at
together, as a Lac-Lip mixture [14,22], and determined
by means of a semi-quantitative method: absent (–), pre-
sent (+), or high (+++) [23]. Histopathological
diagnosis was given in accordance with the WHO clas-
sification of brain tumours [24]. The results were com-
pared with those obtained from the normal brain and
between the examined tumours.
In the examined group there were 26 patients with
glioblastomas, 17 with cerebral metastases, 14 with me -
ningiomas, 3 with oligodendrogliomas, 3 with anaplas-
tic oligodendrogliomas, 6 with fibrillary astrocytomas,
4 with anaplastic astrocytomas, 2 with pilocytic astrocy-
tomas, 2 with haemangiopericytomas, 2 lymphomas, 
6 schwannomas and single patients with Lhermitte-
Duclos disease, choroid plexus papilloma, pituitary ade-
noma and, finally, chondroma. This paper deals only
with tumours of glial origin. The clinical data on 26 pa -
tients with glioblastoma are given in Table 1 and on
patients with other gliomas in Table 2. Mann-Whitney
U test was used for the statistical analysis.
Results
Glioblastoma (WHO grade IV) was diagnosed in 
26 patients: 14 males and 12 females aged 20 to 70
(mean age, 54 years). In the long TE sequence (Fig. 2),
in 11 cases the MRS spectrum showed a high Cho sig-
nal, low peaks of Cr and Naa and a high Lac-Lip sig-
nal. In 5 other spectra, the only difference was that the
Lac-Lip signals were much lower and in the other 7 there
was a negative Lac signal. In 2 cases, there were low
peaks of Cho, Cr and Naa together with a high Lac-Lip
signal. Finally, one spectrum displayed nothing but a high
Lac-Lip signal. In the short TE sequences (Fig. 3) 
13 spectra had a low Cho signal and a high Lac-Lip
No. Age Sex Tumour location
1. 64 F Frontal
2. 54 F Frontal
3. 63 F Temporal
4. 20 F Frontal
5. 38 F Temporal
6. 60 M Temporal
7. 48 M Frontal
8. 63 F Frontal
9. 59 F Parietal
10. 64 M Temporal
11. 53 F Parietal
12. 68 M Parietal
13. 70 M Frontal
14. 50 M Temporal
15. 53 F Frontal
16. 64 M Parietal
17. 45 M Occipital
18. 54 F Frontal
19. 48 M Occipital
20. 64 M Temporal
21. 54 F Frontal
22. 49 M Parietal
23. 66 M Frontal
24. 26 M Parietal
25. 56 M Temporal
26. 55 F Frontal
Table 1. Clinical data of patients with glioblastoma
M – male; F – female
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peak. In the other 4, apart from the aforementioned there
was also a low Cr peak. In 8 cases the main finding was
a high Lac-Lip signal. One spectrum had the following
characteristics: high Cho, low Cr and low Lac-Lip. 
In 3 spectra high mI peaks were identified. Based on 
the spectra obtained in the long TE sequence, the follow -
ing ratios were calculated: Cho/Cr = 5.65 ± 2.38,
Naa/Cr = 1.65 ± 0.67 and Cho/Naa = 4.02 ± 2.09.
The spectra of the short TE sequence gave two other
ratios: Cho/Cr = 1.91 ± 0.72 and mI/Cr = 1.12 ± 0.33.
Anaplastic astrocytoma (WHO grade III) was found
in 4 females (age 21-75, mean 52 years). In the long 
TE sequence (Fig. 4), 3 patients had a high Cho signal
with low Cr and Naa peaks and a negative Lac band.
The only difference in other spectra was a quite high Naa
signal. In the short TE sequence (Fig. 5), all spectra had
high Cho with low Cr and mI signals. In 3 spectra 
there was no Naa band. In every case there was a Lac-
Lip signal which was very high in one patient.
In 6 patients fibrillary astrocytoma was diagnosed
(WHO grade II). Females constituted 2/3 of this group.
The age ranged from 19 to 46 years (mean, 31 years).
In the long TE sequence (Fig. 6), 4 spectra displayed
high Cho with low Cr and Naa signals. In the remain-
ing cases there was also a negative Lac peak. In the short
TE sequence (Fig. 7), 2/3 of the spectra had the fol-
lowing signals: high Cho, low Cr, low Lip-Lac and high
mI. In the remainder, the Lip-Lac peak was absent.
Based on the spectra obtained with the long TE se -
quence, the following ratios were calculated: Cho/Cr =
= 4.53 ± 2.71, Naa/Cr = 1 ± 0.65, Cho/Naa = 3.32
± 1.22. The short TE spectra gave two ratios: Cho/Cr =
= 1.67 ± 0.65 and mI/Cr = 0.92 ± 0.13.
Pilocytic astrocytoma (WHO grade I) was diagnosed
in 2 female patients – 35 and 39 years old. In the long
TE sequence (Fig. 8) both spectra showed a high Cho
and low Cr signal. In one there was a low Naa peak and
a negative Lac band. Another one had no Naa band but
displayed a high Lip signal. In the short TE sequence
(Fig. 9) both spectra were the same, showing high Cho
and lower Cr, Naa and mI with a high Lac-Lip doublet.
Oligodendroglioma (WHO grade II) was diagnos -
ed in 3 patients (2 women and one man, 40-41 years).
The long TE sequence spectra (Fig. 10) showed a high
Cho signal in all cases (it was very high in two). Further -
more, two spectra displayed low Cr and Naa peaks. In
one spectrum apart from the Cho signal there was only
a negative Lac band. In the short TE sequence (Fig. 11)
the following signals were observed: high Cho, low Cr,
mI and Glx. One patient showed a Lip-Lac doublet.
No. Age Sex Histopathology Tumour 
location
1. 75 F Anaplastic astrocytoma Parietal
2. 21 F Anaplastic astrocytoma Frontal
3. 42 F Anaplastic astrocytoma Temporal
4. 71 F Anaplastic astrocytoma Temporal
5. 41 F Oligodendroglioma Frontal
6. 41 M Oligodendroglioma Frontal
7. 40 F Oligodendroglioma Parietal
8. 65 F Anaplastic oligodendroglioma Temporal
9. 63 F Anaplastic oligodendroglioma Parietal
10. 64 F Anaplastic oligodendroglioma Frontal
11. 36 F Fibrillary astrocytoma Frontal
12. 46 F Fibrillary astrocytoma Temporal
13. 26 M Fibrillary astrocytoma Parietal
14. 19 F Fibrillary astrocytoma Parietal
15. 29 M Fibrillary astrocytoma Temporal
16. 30 F Fibrillary astrocytoma Frontal
17. 35 F Pilocytic astrocytoma Cerebellum
18. 39 F Pilocytic astrocytoma Cerebellum
Table 2. Clinical data of patients with gliomas of WHO grade I-III
M – male; F – female
Anaplastic oligodendroglioma (WHO grade III)
was found in 3 women (63-65 years old). All spectra
ob tained with the long TE sequence presented high
Cho and low Cr and Naa signals (Fig. 1). Further-
more, in one patient there was a negative Lac band
and in ano ther a positive Lac-Lip signal. The short
TE sequence spectra revealed only high Lac-Lip
peaks.
The small number of patients restricted statistical
analysis of the metabolic contents only to patients with
the following tumours: glioblastoma, fibrillary astrocy-
toma and anaplastic astrocytoma. All ratios were statis-
tically significantly different from the control. The only
exception was the Cho/Cr ratio in fibrillary astrocytoma
(p = 0.06). Concentration of the metabolites in glioblas-
toma was not significantly different when compared to
anaplastic and fibrillary astrocytomas. Anaplastic astro-
cytomas had higher contents of mI than fibrillary astro-
cytomas (p = 0.02).
All the results are summarized in Tables 3 and 4.
MRS in intracranial tumours of glial origin
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Discussion
MRS of gliomas shows decreased contents of Naa
[25-28] since neurons are superseded by the neoplasm
cells. For the same reason, a decreased level of Cr is
observed [26,28,29]. Furthermore, astrocytomas show
high Cho contents [28,30-32] due to increased synthe-
sis of cellular membranes inside the tumour.
In our patients with diffuse gliomas those features
were apparent in all types of tumours. The only excep-
tion was the Cho/Cr ratio in fibrillary astrocytomas since
it was not significantly different from the one found in
normal brain. This may be explained by the fact that
some of these neoplasms have cellular density only
slightly increased with relative preservation of the local
cytoarchitecture.
Some tumours show Lac and Lip signals, which are
markers of anaerobic metabolism and necrosis [33,34].
There are those who claim that high Lac-Lip concen-
tration helps to distinguish high and low grade gliomas
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Fig. 2. Long-TE spectrum of glioblastoma
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[35-38]. One study does not support this thesis [39].
Another report showed that glioblastomas have a high-
er Lac-Lip concentration than anaplastic astrocytomas
[6]. Interestingly enough, the main source of the Lac-
Lip signal came from the lipids. Nonetheless, the authors
of this study admit that absence of the Lac-Lip signal
does not exclude the diagnosis of high grade glioma. In
our material peak Lac-Lip was present in all instances
of glioblastoma. With one exception the signal was very
high (++) in the STEAM sequence. In the patients
with anaplastic astrocytoma this band was always present
but it was high only in one case. In contrast, fibrillary
astrocytoma displayed Lac-Lip in 2/3 of the cases, none
of which reached a high level. Hence, it seems that Lac-
Lip signal magnitude may be of assistance in distin-
guishing WHO grade II from WHO II and III
gliomas.
Several reports state that Cho contents measured
with the Cho/Cr ratio increase with the grade of astro-
cytoma [35,38,40-44]. This was also proven in vitro
Fig. 4. Long-TE spectrum of anaplastic astrocytoma
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Fig. 5. Short-TE spectrum of anaplastic astrocytoma
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[44-46]. However, there are papers claiming that this
ratio might be equal or even lesser in WHO grade IV
than in astrocytomas grade II-III [36,39,45].
The decrease of Cho/Cr ratio in glioblastoma is
explained by the presence of necrosis in these tumours
[36]. Our study did not show a statistically significant
difference in Cho/Cr ratio between different gliomas.
There were suggestions that the Naa/Cr ratio de -
creases with increased malignancy of glioma [44,46,47].
Other authors, however, do not confirm this correlation
[35,39,41,42,44,45]. Also in our study, we found no
significant difference in Naa/Cr ratio in different types
of gliomas. The absence of the expected decrease of
Naa/Cr may result from superimposing the lipid signal
on the Naa band during the short TE sequence [48].
Despite certain discrepancies, it was suggested that
MRS can distinguish astrocytomas of grade II from
grade III and IV with the accuracy exceeding 95% [49].
The most difficult task remains to show an MRS dif-
ference between anaplastic astrocytomas and glioblas-
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Fig. 6. Long-TE spectrum of fibrillary astrocytoma
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toma. This is chiefly due to difficulties in placing the
voxel in the representative part of the neoplasm [49].
Another potentially useful metabolite is mI. A study
on in vitro MRS showed that mI concentration was the
only factor discriminating astrocytomas of different grades
[50]. It was suggested that mI/Cr level is the highest in
WHO grade II astrocytomas [51], whereas the level
observed in anaplastic astrocytoma was lower than in nor-
mal brain but still greater than the one found in glioblas-
toma. This was explained by the fact that in malignant
gliomas mI is used for synthesis of phosphatidylinositol,
whose derivative products (diacylglycerol) are indirect acti-
vators of metalloproteinases responsible for spreading of
the neoplasm in the brain [52-54]. To date, the increase
of mI in grade II astrocytomas has not been explained.
However, also opposite suggestions can be encoun-
tered in the literature [55]. One in vitro study showed
that glioblastomas have a greater mI/Cr ratio than grade
II and III astrocytomas [56]. In our study the mI/Cr
ratio was greater in grade III than in grade II astrocy-
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Fig. 8. Long-TE spectrum of pilocytic astrocytoma
Fig. 9. Short-TE spectrum of pilocytic astrocytoma
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Fig. 11. Short-TE spectrum of oligodendroglioma
tomas and there was no significant difference in mI/Cr
between glioblastomas and other types of gliomas. More-
over, all astrocytomas had a significantly greater mI/Cr
value than the normal brain. Apparently, our results did
not support the data given in the discussed paper. This
might be due to the fact that our study involved only
patients with newly diagnosed tumours whilst the sub-
jects in the discussed article had been operated on and
given radio- and/or chemotherapy 1 to 3 years before
the MRS was done.
According to some studies, glycine may be found in
the spectra of some WHO grade II gliomas [57]. If pre-
sent, this metabolite may play some role in the glioma
grading. In our study no single glycine peak was iden-
tified in any of the glioma spectra.
There are no reports in the literature concerning MRS
discrimination of grade I and II astrocytomas. Usually,
these neoplasms are placed together in a single group to
be compared with other tumours. There is a single paper
which gives a brief account of a spectrum of pilocytic
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astrocytoma located in the cerebral hemisphere [49]. 
The MRS spectrum obtained during the long TE se -
quence contained a high Cho signal, somewhat decreased
bands of Cr and Naa, with a small negative doublet Lac.
The specific feature of this tumour as compared to high-
er grade gliomas was a relatively high level of both Cr and
Naa. In our patients MRS spectra of the pilocytic astro-
cytomas showed a high Cho signal with low Cr and Naa
in the presence of negative Lac and high Lip. The short
TE sequence revealed in both our cases a spectrum with
a high Cho signal, lower Cr, Naa and mI with a high Lac-
Lip doublet. The increase of Cho calculated on the basis
of the Cho/Cr ratio was 5.47 ± 0.81; thus it was compa-
rable with glioblastomas and anaplastic astrocytomas 
but apparently higher than in fibrillary astrocytomas. 
The high Cho/Cr probably results from a decrease of Cr
concentration. This in turn could be explained by con-
cealing a part of the Cr peak in the descending portion of
the Cho signal curve or placing the voxel partly over a cys-
tic part of the tumour. The value Naa/Cr = 2.58 ± 0.39
was greater than in other astrocytomas. The increased
contents of Naa in comparison to grade II-IV gliomas
was confirmed by the Cho/Naa ratio of 2.14 ± 0.64, low-
er than in other tumours. According to the previously dis-
cussed papers, the higher Naa content is characteristic for
low grade gliomas. The high Lac-Lip signals are proba-
bly caused by the presence of these metabolites in the cys-
tic part of the tumour.
The MRS spectrum of oligodendrogliomas is very
similar to that found in astrocytomas: high Cho signal,
decreased Naa and Cr with present Lac-Lip and mI.
A specific feature is the presence of a glutamate/gluta-
mine peak (Glx). This was confirmed in the literature as
the only factor discriminating oligodendrogliomas from
astrocytomas [58]. Similar findings were confirmed in
vitro [59]. In our 6 patients with oligodendrogliomas,
a clear Glx signal was identified in all 3 WHO grade II
tumours and in 1 out of 3 WHO grade III neoplasms.
In contrast, this band was not present in 9 cases with
astrocytomas of grade II and III. This is consistent with
the literature. The study quoted above [58] showed that
Glx Ala Lac-Lip
PRESS STEAM
Glioblastoma – – 15++ 26++
2+ 1+
Fibrillary – – 2+ 4+
astrocytoma 4– 2–
Anaplastic – – 4+ 1++
astrocytoma 3+
Pilocytic – – 2+ 2++
astrocytoma
Oligodendroglioma 3+ – 1+ 1+
2– 2–
Anaplastic 1+ – 1++ 3++
oligodendroglioma 1+
1–
Table 4. Other metabolites found in the examined gliomas
Ala – alanine; Glx – glutamate; Lac – lactates; Lip – lipids; PRESS – Point Resolved Spec-
troscopy; STEAM – Stimulated Echo Acquisition Mode absent (–), present (+), high (+++),
the numbers indicate how many patients had the respective result
Cho/Cr Naa/Cr Cho/Naa mI/Cr
PRESS STEAM PRESS STEAM PRESS STEAM STEAM
Control 1.12 ± 0.25 1.06 ± 0.34 2.1 ± 0.3 1.86 ± 0.54 0.52 ± 0.1 0.59 ± 0.12 0.46 ± 0.07
Glioblastoma 5.65 ± 2.38 1.91 ± 0.72 1.65 ± 0.67 – 4.02 ± 2.09 – 1.12 ± 0.33 
p = 0.0009 p = 0.0299 p = 0.0059 p = 0.0006 p = 0.0068
Fibrillary 4.53 ± 2.71 1.67 ± 0.65 1 ± 0.65 – 3.32 ± 1.22 – 0.92 ± 0.13
astrocytoma p = 0.0106 p = 0.0059 p = 0.0059 p =0.0008
Anaplastic 5.49 ± 3.16 2.69 ± 1.11 1.11 ± 0.2 – 4.1 ± 2.53 – 2.98 ± 1.83 
astrocytoma p = 0.0105 p = 0.0128 p = 0.0196 p = 0.0201 p = 0.0068
Pilocytic 5.41 ± 0.81 4.04 2.58 ± 0.39 – 2.14 ± 0.64 – 3.19
astrocytoma
Oligodendroglioma 2.94 4.1 ± 0.47 0.99 – 2.98 – –
Anaplastic 4.96 – – – – – –
oligodendroglioma
Table 3. Metabolite ratios (mean value and standard deviation) in different gliomas and in the normal brain. Differences between each tumour and the control were
recognised as statistically significant if p < 0.05
Cho – choline; Cr – creatinine; mI – myo-inositol; Naa – N-acetyl aspartate; PRESS – Point Resolved Spectroscopy; STEAM – Stimulated Echo Acquisition Mode
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the high Lac-Lip signal is characteristic for anaplastic
oligodendroglioma. This was confirmed in our material
as the high Lac-Lip peak appeared in all 3 patients with
this tumour. In oligodendroglioma (WHO grade II),
there was only one instance of a low (+) Lac-Lip sig-
nal. Hence, the assessment of concentration of those
metabolites may be of assistance in distinguishing oligo-
dendrogliomas from anaplastic oligodendrogliomas.
Conclusions
At present, it seems that in vivo MR spectroscopy
cannot be used as a reliable method for glioma grading.
Nevertheless, it is useful in discrimination between
WHO grade I and WHO grade II astrocytomas as well
as oligodendrogliomas and other gliomas.
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